Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives
October 07 2019 - 9:00AM
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases, announced that it has engaged
A.G.P./Alliance Global Partners as financial advisor to explore and
evaluate strategic alternatives to enhance shareholder value.
Potential strategic alternatives that may be
explored or evaluated by the Company as part of this process
include an acquisition, merger, reverse merger, other business
combination, sale of assets, licensing or other strategic
transactions involving the Company. The Company does not intend to
discuss or disclose further developments during this process unless
and until its Board of Directors has approved a specific action or
otherwise determined that further disclosure is appropriate.
About Ritter
PharmaceuticalsRitter Pharmaceuticals, Inc.
(www.RitterPharma.com, @RitterPharma) develops innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases. The Company is exploring the therapeutic
potential that gut microbiome changes may have on
treating/preventing a variety of diseases including
gastrointestinal diseases, cancer, metabolic, and liver
disease.
Forward-Looking StatementsThis
press release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that express the current beliefs and expectations of Ritter
Pharmaceuticals’ management. Any statements contained herein that
do not describe historical facts are forward-looking statements,
including statements related to a potential acquisition, merger,
reverse merger, other business combination, sales of assets,
licensing or other strategic transactions involving the Company.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results, performance and achievements to
differ materially from those discussed in such forward-looking
statements. Some of the factors that could affect our actual
results are included in the periodic reports on Form 10-K and Form
10-Q that we file with the Securities and Exchange Commission. The
Company cautions readers not to place undue reliance on any
forward-looking statements, which speak only as of the date they
were made. The Company undertakes no obligation to update or revise
forward-looking statements, except as otherwise required by law,
whether as a result of new information, future events or otherwise.
The Company does not expect to disclose developments with respect
to the process expressed above unless and until the evaluation of
strategic alternatives has been completed or the board of directors
has concluded that disclosure is appropriate or legally
required.
ContactsInvestor Contact: John Beck
310-203-1000 john@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Sep 2023 to Sep 2024